Cargando…
CRI iAtlas: an interactive portal for immuno-oncology research
The Cancer Research Institute (CRI) iAtlas is an interactive web platform for data exploration and discovery in the context of tumors and their interactions with the immune microenvironment. iAtlas allows researchers to study immune response characterizations and patterns for individual tumor types,...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658727/ https://www.ncbi.nlm.nih.gov/pubmed/33214875 http://dx.doi.org/10.12688/f1000research.25141.1 |
_version_ | 1783608732824895488 |
---|---|
author | Eddy, James A. Thorsson, Vésteinn Lamb, Andrew E. Gibbs, David L. Heimann, Carolina Yu, Jia Xin Chung, Verena Chae, Yooree Dang, Kristen Vincent, Benjamin G. Shmulevich, Ilya Guinney, Justin |
author_facet | Eddy, James A. Thorsson, Vésteinn Lamb, Andrew E. Gibbs, David L. Heimann, Carolina Yu, Jia Xin Chung, Verena Chae, Yooree Dang, Kristen Vincent, Benjamin G. Shmulevich, Ilya Guinney, Justin |
author_sort | Eddy, James A. |
collection | PubMed |
description | The Cancer Research Institute (CRI) iAtlas is an interactive web platform for data exploration and discovery in the context of tumors and their interactions with the immune microenvironment. iAtlas allows researchers to study immune response characterizations and patterns for individual tumor types, tumor subtypes, and immune subtypes. iAtlas supports computation and visualization of correlations and statistics among features related to the tumor microenvironment, cell composition, immune expression signatures, tumor mutation burden, cancer driver mutations, adaptive cell clonality, patient survival, expression of key immunomodulators, and tumor infiltrating lymphocyte (TIL) spatial maps. iAtlas was launched to accompany the release of the TCGA PanCancer Atlas and has since been expanded to include new capabilities such as (1) user-defined loading of sample cohorts, (2) a tool for classifying expression data into immune subtypes, and (3) integration of TIL mapping from digital pathology images. We expect that the CRI iAtlas will accelerate discovery and improve patient outcomes by providing researchers access to standardized immunogenomics data to better understand the tumor immune microenvironment and its impact on patient responses to immunotherapy. |
format | Online Article Text |
id | pubmed-7658727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | F1000 Research Limited |
record_format | MEDLINE/PubMed |
spelling | pubmed-76587272020-11-18 CRI iAtlas: an interactive portal for immuno-oncology research Eddy, James A. Thorsson, Vésteinn Lamb, Andrew E. Gibbs, David L. Heimann, Carolina Yu, Jia Xin Chung, Verena Chae, Yooree Dang, Kristen Vincent, Benjamin G. Shmulevich, Ilya Guinney, Justin F1000Res Software Tool Article The Cancer Research Institute (CRI) iAtlas is an interactive web platform for data exploration and discovery in the context of tumors and their interactions with the immune microenvironment. iAtlas allows researchers to study immune response characterizations and patterns for individual tumor types, tumor subtypes, and immune subtypes. iAtlas supports computation and visualization of correlations and statistics among features related to the tumor microenvironment, cell composition, immune expression signatures, tumor mutation burden, cancer driver mutations, adaptive cell clonality, patient survival, expression of key immunomodulators, and tumor infiltrating lymphocyte (TIL) spatial maps. iAtlas was launched to accompany the release of the TCGA PanCancer Atlas and has since been expanded to include new capabilities such as (1) user-defined loading of sample cohorts, (2) a tool for classifying expression data into immune subtypes, and (3) integration of TIL mapping from digital pathology images. We expect that the CRI iAtlas will accelerate discovery and improve patient outcomes by providing researchers access to standardized immunogenomics data to better understand the tumor immune microenvironment and its impact on patient responses to immunotherapy. F1000 Research Limited 2020-08-24 /pmc/articles/PMC7658727/ /pubmed/33214875 http://dx.doi.org/10.12688/f1000research.25141.1 Text en Copyright: © 2020 Eddy JA et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Software Tool Article Eddy, James A. Thorsson, Vésteinn Lamb, Andrew E. Gibbs, David L. Heimann, Carolina Yu, Jia Xin Chung, Verena Chae, Yooree Dang, Kristen Vincent, Benjamin G. Shmulevich, Ilya Guinney, Justin CRI iAtlas: an interactive portal for immuno-oncology research |
title | CRI iAtlas: an interactive portal for immuno-oncology research |
title_full | CRI iAtlas: an interactive portal for immuno-oncology research |
title_fullStr | CRI iAtlas: an interactive portal for immuno-oncology research |
title_full_unstemmed | CRI iAtlas: an interactive portal for immuno-oncology research |
title_short | CRI iAtlas: an interactive portal for immuno-oncology research |
title_sort | cri iatlas: an interactive portal for immuno-oncology research |
topic | Software Tool Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658727/ https://www.ncbi.nlm.nih.gov/pubmed/33214875 http://dx.doi.org/10.12688/f1000research.25141.1 |
work_keys_str_mv | AT eddyjamesa criiatlasaninteractiveportalforimmunooncologyresearch AT thorssonvesteinn criiatlasaninteractiveportalforimmunooncologyresearch AT lambandrewe criiatlasaninteractiveportalforimmunooncologyresearch AT gibbsdavidl criiatlasaninteractiveportalforimmunooncologyresearch AT heimanncarolina criiatlasaninteractiveportalforimmunooncologyresearch AT yujiaxin criiatlasaninteractiveportalforimmunooncologyresearch AT chungverena criiatlasaninteractiveportalforimmunooncologyresearch AT chaeyooree criiatlasaninteractiveportalforimmunooncologyresearch AT dangkristen criiatlasaninteractiveportalforimmunooncologyresearch AT vincentbenjaming criiatlasaninteractiveportalforimmunooncologyresearch AT shmulevichilya criiatlasaninteractiveportalforimmunooncologyresearch AT guinneyjustin criiatlasaninteractiveportalforimmunooncologyresearch |